Lignan Intake and Risk of Coronary Heart Disease
- PMID: 34384548
- PMCID: PMC8432598
- DOI: 10.1016/j.jacc.2021.05.049
Lignan Intake and Risk of Coronary Heart Disease
Abstract
Background: Evidence regarding lignan consumption in relation to coronary heart disease (CHD) risk remains limited and mixed.
Objectives: The aim of this study was to prospectively examine associations between lignan intake and CHD risk in U.S. men and women.
Methods: We prospectively followed 214,108 men and women in 3 cohorts who did not have cardiovascular disease or cancer at baseline. Diet was repeatedly assessed using a validated food frequency questionnaire every 2-4 years since baseline.
Results: During 5,517,225 person-years of follow-up, we documented 10,244 CHD cases, including 6,283 nonfatal myocardial infarction and 3,961 fatal CHD cases. In multivariable-adjusted analyses, comparing extreme quintiles, the pooled hazard ratios of CHD were 0.85 (95% CI: 0.79-0.92) for total lignans, 0.76 (95% CI: 0.71-0.82) for matairesinol, 0.87 (95% CI: 0.81-0.93) for secoisolariciresinol, 0.89 (95% CI: 0.83-0.95) for pinoresinol, and 0.89 (95% CI: 0.83-0.95) for lariciresinol (all P values for trend ≤0.003). Nonlinear relationships were found for total lignan, matairesinol, and secoisolariciresinol: the risk reduction plateaued at intakes above approximately 300 μg/d, 10 μg/d, and 100 μg/d, respectively (P < 0.01 for all nonlinearity). The inverse associations for total lignan intake appeared to be more apparent among participants with higher total fiber intake (P = 0.04 for interaction). In addition, lignan intake was more strongly associated with plasma concentrations of enterolactone when fiber intake was higher.
Conclusions: Increased long-term intake of lignans was associated with a significantly lower risk of total CHD in both men and women. Possible synergistic effects may exist between lignan and fiber intake in relation to CHD risk reduction, possibly through enhancing the production of enterolignans.
Keywords: coronary heart disease; lignan; prospective cohorts.
Copyright © 2021 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures The NHS, NHSII, and HPFS studies and the current analysis are supported by National Institutes of Health grants UM1 CA186107, P01 CA87969, R01 CA49449, R01 HL034594, R01 HL088521, U01 CA176726, R01 CA67262, U01 CA167552, R01 HL035464, R01 HL060712, and R01 DK120870. The funding sources did not participate in the design or conduct of the study; collection, management, analysis or interpretation of the data; or preparation, review, or approval of the manuscript. The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures
Comment in
-
Plant Polyphenols Lignans and Cardiovascular Disease.J Am Coll Cardiol. 2021 Aug 17;78(7):679-682. doi: 10.1016/j.jacc.2021.06.014. J Am Coll Cardiol. 2021. PMID: 34384549 No abstract available.
-
Plant-Based Diet, Gut Microbiota, and Bioavailability of Lignans.J Am Coll Cardiol. 2021 Dec 14;78(24):e311. doi: 10.1016/j.jacc.2021.09.1369. J Am Coll Cardiol. 2021. PMID: 34886974 No abstract available.
-
Reply: Plant-Based Diet, Gut Microbiota, and Bioavailability of Lignans.J Am Coll Cardiol. 2021 Dec 14;78(24):e313. doi: 10.1016/j.jacc.2021.10.007. J Am Coll Cardiol. 2021. PMID: 34886975 No abstract available.
References
-
- Heinonen S, Nurmi T, Liukkonen K, et al. In vitro metabolism of plant lignans: New precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem 2001;49(7):3178–86. - PubMed
-
- Lignans Adlercreutz H. and human health. Crit Rev Clin Lab Sci 2007;44(5–6):483–525. - PubMed
-
- Landete JM., Arqués J, Medina M, Gaya P, de Las Rivas BD, Muñoz R. Bioactivation of Phytoestrogens: Intestinal Bacteria and Health. Crit Rev Food Sci Nutr 2016;56(11):1826–43. - PubMed
-
- Mendelsohn ME., Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340(23):1801–11. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 CA138962/CA/NCI NIH HHS/United States
- R01 CA067262/CA/NCI NIH HHS/United States
- U01 CA176726/CA/NCI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
- R01 DK120870/DK/NIDDK NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- R01 HL034594/HL/NHLBI NIH HHS/United States
- UM1 CA186107/CA/NCI NIH HHS/United States
- R01 HL035464/HL/NHLBI NIH HHS/United States
- R01 HL088521/HL/NHLBI NIH HHS/United States
- R01 CA049449/CA/NCI NIH HHS/United States
- R01 HL060712/HL/NHLBI NIH HHS/United States
- U01 CA167552/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
